PRESS RELEASE : Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share

DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend 
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share 
2021-03-18 / 17:45 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Media Release as of March 18, 2021 
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share 
All proposals of BB Biotech AG's Board of Directors were approved by shareholders at its Annual General Meeting held 
today. In accordance with the COVID-19 Ordinance 2, the voting rights of shareholders were exclusively exercised 
through the independent proxy as per their instructions, since shareholders were not allowed to attend the meeting in 
person. 
Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.60 per share. Payment will be made on March 
24, 2021, the record date is March 23, 2021 and the ex-dividend date is March 22, 2021. 
Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell, Dr. Susan Galbraith, 
Prof. Dr. Mads Krogsgaard Thomsen and Dr. Thomas von Planta to another one-year term of office. 
 
Investor Relations 
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. [phone] 
Dr. Silvia Schanz, [e-mail] 
Maria-Grazia Iten-Alderuccio, [e-mail] 
Claude Mikkelsen, [e-mail] 
Media Relations 
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. [phone] 
Tanja Chicherio, [e-mail] 
TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland, Tel. [phone] 
Thomas Egger, [e-mail] 
www.bbbiotech.com 
 
Company profile 
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in 
Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are 
mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech 
builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the 
experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions. 
Disclaimer 
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such 
statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject 
to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and 
its directors and officers accept no responsibility in that regard. All forward-looking statements included in this 
release are made only as of the date of this release and BB Biotech and its directors and officers undertake no 
obligation to update any forward-looking statements as a result of new information, future events or other factors. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        [phone] 
E-mail:       [e-mail] 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1176751 
 
End of News   DGAP News Service 
=------------ 

1176751 2021-03-18

(END) Dow Jones Newswires

March 18, 2021 12:47 ET (16:47 GMT)